Irbesartan Zydus (Irbesartan)

Irbesartan blocks the angiotensin II type 1 (AT1) receptors on blood vessels and adrenal tissue. This prevents angiotensin II‑mediated vasoconstriction and aldosterone release, leading to relaxed blood vessels, reduced sodium and water retention, and ultimately lower blood pressure.

The appropriate dose of Irbesartan Zydus is determined by the prescribing clinician based on the individual’s medical condition, response to therapy, and renal function. Patients should follow the dosage instructions provided by their healthcare professional.

Irbesartan is contraindicated during pregnancy because it can cause fetal toxicity and injury. Limited data are available for breastfeeding; therefore, use is generally not recommended unless the potential benefit justifies the potential risk to the infant.

To order Irbesartan Zydus, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Irbesartan belongs to the ARB class, offering blood‑pressure control similar to ACE inhibitors but with a lower incidence of cough and angioedema. Unlike some diuretics, it does not increase uric acid levels, making it a suitable alternative for patients who cannot tolerate ACE inhibitors or certain diuretics.

Irbesartan Zydus tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original container, protect from moisture and light, and store out of reach of children.

Irbesartan Zydus is taken orally as a tablet, with or without food. Patients should swallow the tablet whole with a glass of water and follow the dosing schedule prescribed by their healthcare provider.

The most serious adverse events include angioedema (swelling of the face, lips, tongue), severe hyperkalemia (high blood potassium), and acute kidney injury or a rapid rise in serum creatinine. Patients should seek immediate medical attention if they experience any of these symptoms.

Irbesartan Zydus should not be used by pregnant women, individuals with known hypersensitivity to irbesartan or any ARB component, and patients with severe renal impairment (eGFR <30 mL/min/1.73 m²) unless specifically directed by a specialist.